Zohar Koren, PhD
Founder & CEO
Claimed by owner SciCann Therapeutics
Former names:
Cannabis and Cannabinoid Pharmaceuticals
SciCann Therapeutics
www.globenewswire.com
•
Oct 2, 2019
SciCann Therapeutics receives notice of allowance for its enhanced CBD therapy US patent for NASH
www.globenewswire.com
•
Feb 21, 2019
SciCann Therapeutics launch liver disease research program in Tel Aviv University
www.businesswire.com
•
Nov 29, 2018
FSD Pharma and SciCann Therapeutics to Present at the iCDP Summit in Boston
www.globenewswire.com
•
Nov 6, 2018
SciCann Therapeutics Announces Positive ISA Report for "Steady Stomach" CBD Combination Therapy Patent
www.newswire.ca
•
Sep 23, 2018
FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University
www.globenewswire.com
•
Aug 23, 2018
SciCann Therapeutics reports positive pre-clinical results for proprietary CBD combination product
www.prnewswire.com
•
Aug 16, 2018
FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel
www.cannabisbusinesstimes.com
•
Jun 7, 2018
FSD Pharma Secures Exclusive Rights in Canada for Line of Proprietary Products, Access to Cannabinoid Science Research Platform in Israel
www.thenewswire.com
•
Dec 12, 2017
Global Cannabis Partners with Leading Israeli Pharmaceutical Company to Provide Medical Cannabis Data to Blockchain
About
SciCann Therapeutics is a CanadianIsraeli pharmaceutical company that develops and commercializes pharmaceutical products that target and modulate the endocannabinoid system, including new therapeutic agents, drug candidates, novel cannabis genetics, and personalized treatment tools.
SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases, and inflammatory disorders. The company develops a line of proprietary products for the treatment of chosen life-threatening conditions that present a high level of unmet need.
SciCann Therapeutics holds a diversified portfolio of intellectual property and ownerships in ventures operating in cannabinoid science. It maintains a wide network of strategic and synergistic collaborations with research institutes and commercial companies in the space.
The company's R&D is performed in Israel with commercialization in Canada.
SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases, and inflammatory disorders. The company develops a line of proprietary products for the treatment of chosen life-threatening conditions that present a high level of unmet need.
SciCann Therapeutics holds a diversified portfolio of intellectual property and ownerships in ventures operating in cannabinoid science. It maintains a wide network of strategic and synergistic collaborations with research institutes and commercial companies in the space.
The company's R&D is performed in Israel with commercialization in Canada.
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
Israel, Canada
News
(9)
www.globenewswire.com
•
Oct 2, 2019
SciCann Therapeutics receives notice of allowance for its enhanced CBD therapy US patent for NASH
www.globenewswire.com
•
Feb 21, 2019
SciCann Therapeutics launch liver disease research program in Tel Aviv University
www.businesswire.com
•
Nov 29, 2018
FSD Pharma and SciCann Therapeutics to Present at the iCDP Summit in Boston
www.globenewswire.com
•
Nov 6, 2018
SciCann Therapeutics Announces Positive ISA Report for "Steady Stomach" CBD Combination Therapy Patent
www.newswire.ca
•
Sep 23, 2018
FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University
www.globenewswire.com
•
Aug 23, 2018
SciCann Therapeutics reports positive pre-clinical results for proprietary CBD combination product
www.prnewswire.com
•
Aug 16, 2018
FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel
www.cannabisbusinesstimes.com
•
Jun 7, 2018
FSD Pharma Secures Exclusive Rights in Canada for Line of Proprietary Products, Access to Cannabinoid Science Research Platform in Israel
www.thenewswire.com
•
Dec 12, 2017
Global Cannabis Partners with Leading Israeli Pharmaceutical Company to Provide Medical Cannabis Data to Blockchain
The Team
(2)
SIBCCL
Sheldon Inentash, B.Comm, CA, CPA, LL.D.
Founder
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Undisclosed Round
$3M
Jun 2018
1 Investors
$3M
Media gallery
(0)Locations
Israel
Gan Ner, Israel
Offices Abroad
69 Yonge St, Aurora, Toronto, Ontario, Canada
Locations
Israel
Gan Ner, Israel
Offices Abroad
69 Yonge St, Aurora, Toronto, Ontario, Canada
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,